In the European Union, 4.5 million people are estimated to have AF.
• Recognized limitations of warfarin lead to wide variability in patients' responses to therapy, which raises the risk of stroke or bleeding when anticoagulant effect is outside the narrow therapeutic range.
• In contrast to warfarin, new oral anticoagulants meet the need for predictable anticoagulation with fixed dosing and without a requirement for laboratory monitoring.
• While the new oral anticoagulants are more expensive per unit than warfarin, an associated reduction in clinical events may favorably influence medical costs and should be offset against the increased financial costs per unit.
What is already known about this subject
• Additional information for decision makers on the associated risk-benefit in deciding whether to include a new oral anticoagulant on the formulary.
• While promising economic analyses comparing new anticoagulants with warfarin are based largely on clinical trial data and decision-analysis models, this review focuses on cost of realworld situations based on observational study.
• Cost-effectiveness studies comparing newer anticoagulants with warfarin are warranted before the results can be directly applied to the real-world setting.
and follow-up care), indicating that AF is a major economic burden. 12 Stroke and heart failure are the major complications of AF and are responsible for the majority of the excess cost associated with AF. A somewhat lower estimate of the cost of AF was provided by a retrospective analysis of 3 U.S. databases using 2001 data. 13 This analysis estimated that the total annual cost for the treatment of AF was $6.65 billion in 2005 U.S. dollars. Of this, $2.93 billion (44%) was as a result of direct costs for hospitalization where the principal diagnosis was AF; $1.95 billion (29%) was attributed to the incremental inpatient cost of AF as a comorbid condition; $1.53 billion (23%) was attributed to the outpatient treatment of AF; and $235 million (4%) was attributed to prescription drugs. The authors acknowledged that their cost estimate was conservative, as it did not include all encounters with AF as a comorbidity; did not take into account the costs of nursing home and home health care; and did not capture the cost of long-term anticoagulation and stroke prevention. Another retrospective, observational cohort study using administrative claims from the MarketScan Commercial and Medicare Supplemental research databases (2004 to 2006) provided a more recent estimate of the national cost of AF.
14 Patients with AF (N = 89,066) were propensity score-matched (1:1) with non-AF control subjects and medical costs in 2008 U.S. dollars were examined over 1 year postindex. National incremental costs of AF were based on age-and sex-specific AF prevalence projections for 2010. For AF versus control subjects, mean annual inpatient costs per patient were $7,841 versus $2,622 (P < 0.001; incremental cost, $5,218); outpatient medical costs were $9,225 versus $5,629 (P < 0.001, incremental cost, $3,596); and outpatient pharmacy costs were $3,605 versus $3,714 (P < 0.001, incremental cost, −$109). The total incremental cost of AF was $8,705 per patient. On the basis of U.S. age-and sex-specific prevalence data for 2010, the national incremental AF cost is estimated to range from $6.0 to $26.0 billion.
An analysis of a U.S. Medicare database followed a random sample of 55,260 patients with AF for 1 year after diagnosis in 2003 to identify the total direct treatment costs of AF. 15 Each patient was matched with an age-, sex-, and race-matched control. The mean incremental cost of treating AF was $16,311 (standard deviation [SD] $25,391) in the 1-year post-index period for a patient with AF compared with a patient without AF (adjusted for additional confounders, $14,199, 95% CI $13,201-15,001). Much of the cost was attributable to the incidence of stroke and heart failure in the year after diagnosis, as significantly greater proportions of patients with AF experienced these complications than did Medicare beneficiaries without AF.
A multivariate analysis using a privately insured database (1999) (2000) (2001) (2002) , from employers in the United States) assessed the direct annual costs associated with AF. 16 Excess medical costs estimated for AF patients (N = 3,944) were defined as the reduction in clinical events associated with these new anticoagulants may impact the medical costs and should be offset against the increased financial costs per unit. In particular, lower rates of stroke and systemic embolism were associated with dabigatran (150 milligrams [mg] twice a day: relative risk 0.66, 95% confidence interval [CI] 0.53 to 0.82, P < 0.001 for superiority) and apixaban (5 mg twice a day: hazard ratio 0.79, 95% CI 0.66 to 0.95, P < 0.001 for noninferiority, P = 0.01 for superiority) in comparison with warfarin. 8, 9 Rivaroxaban (20 mg daily: hazard ratio 0.79, 95% CI 0.66 to 0.96, P < 0.001 for superiority) was similar in efficacy to warfarin for the prevention of stroke or systemic embolism. 10 As with warfarin, bleeding is a serious complication associated with new oral anticoagulants. Indeed, dabigatran (150 mg twice daily) and rivaroxaban have been associated with similar rates of major hemorrhage in comparison with warfarin (dabigatran, relative risk 0.93, 95% CI 0.81-1.07, P = 0.31; rivaroxaban, hazard ratio 1.04, 95% CI 0.90-1.20, P = 0.58), while apixaban has been associated with lower rates of major hemorrhage (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P < 0.001) in comparison with warfarin. [8] [9] [10] Costs associated specifically with warfarin should be offset against the financial costs of these newer agents. For example, a resource utilization study calculated the total costs of warfarin per year for 402 patients with nonvalvular AF. 11 Drug costs accounted for 13.6% of the total cost per patient-year, while monitoring costs (including INR tests, travel, missed work, nurse visits, and postage) accounted for 56% and the costs of managing bleeding accounted for 29.7%.
In making a decision regarding whether to include a new oral anticoagulant on the formulary, decision makers need to balance the benefit and the harm associated with each therapeutic choice and then conduct a value assessment in terms of the excess benefit versus the cost. In order to estimate the cost accurately, there needs to be a solid knowledge base, not only including the cost differences of the various drugs, but also taking into account the costs offset by avoiding the negative consequences of anticoagulation. These consequences include the cost of monitoring, the cost of bleeding events when patients are above the therapeutic range, and the cost of stroke when patients are below the therapeutic range. This review surveyed the literature, with a focus on studies conducted in the United States, to highlight the costs of anticoagulant therapy beyond its unit price per tablet and present this information collectively in one place to support formulary decisions.
■■ Design Overall Costs of AF to Health Care Systems
The annual direct and indirect costs of stroke care in the United States have been estimated at $73.7 billion (in 2010 U.S. dollars), with a mean lifetime cost of ischemic stroke per patient of $140,048 (including inpatient care, rehabilitation, difference in average annual costs between AF and control patients. A non-AF control sample was randomly selected (1:1 ratio) with characteristics (i.e., age, gender, health plan) matched to AF patients. After adjusting for coexisting conditions and demographic factors, the excess annual direct cost of AF was $14,875, where care for patients with AF was approximately 5 times as costly as for non-AF individuals ($18,454 vs. $3,579, P < 0.01). The study found that hospital costs were higher among AF patients ($8,486 vs. $742) partly because of the initial stay, but also because of the frequent need for readmission. A similar result was also observed in another retrospective study of claims data (January 2004 to December 2007) where 42.4% of AF patients were rehospitalized within 1 year. 17 This study of 32,905 adults discharged after a first admission for AF or atrial flutter (AFL) evaluated all direct health care costs over the 12-month period following the first observed hospitalization. Annual total mean per-patient costs were $38,270, with inpatient costs ($22,582) representing 59% of total costs. For patients who died during hospitalizations, costs were $27,889 for the hospitalization during which they died. Annual outpatient costs were $15,689 per patient.
As may be expected, the costs of AF/AFL increase when patients have comorbidities. The scale of this increase was illustrated in a retrospective cohort study using data extracted from a U.S. Medicare database between January 2006 and March 2009. 18 In this study, the costs of managing patients with AF/AFL and at least 1 additional risk factor (hypertension, diabetes, arterial/pulmonary embolism, stroke/transient ischemic attack) but without prior heart failure or transient AF/AFL were compared with the costs of managing patients with AF/AFL only. A total of 58,555 patients with AF/AFL with at least 1 additional risk factor and 58,555 matched controls with AF only were included. Over a 12-month index period, the inpatient costs for the patients with AF/AFL and at least 1 additional risk factor compared with patients with only AF/ AFL were $9,613 (SD $25,407) versus $2,625 (SD $11,597; P < 0.0001); the outpatient costs were $9,447 (SD $15,062) versus $4,906 (SD $11,715; P < 0.0001); and the prescription drug costs were $3,430 (SD $3,637) versus $2,618 (SD $3,374; P < 0.0001). This study illustrated the high-cost burden of inpatient and outpatient management of patients with AF/AFL with additional risk factors and without prior heart failure.
Among the newer oral anticoagulants, the cost-effectiveness of dabigatran has been evaluated in hypothetical realworld AF populations. The cost-effectiveness of dabigatran was calculated based on a decision-analysis (Markov) model and results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Shah and Gage (2011) found dabigatran 150 mg twice daily to be cost-effective in an AF population at high risk of hemorrhage or stroke in comparison with warfarin unless the time in therapeutic range was excellent (> 72.6%) for warfarin. 19 The incremental cost-effectiveness ratio (ICER) for dabigatran compared with warfarin was approximately $86,000 per quality-adjusted life year (QALY). 19 The rates of adverse events varied over a long period; however, adverse events within 2 years of follow-up were applied to model cost-effectiveness for a 20-year time horizon. Second, early RE-LY data were used in this study although updated RE-LY results were available. 20 In contrast, 2 Freeman et al. studies (2011) estimated an ICER of $12,386 per QALY gained with dabigatran. 21, 22 In Freeman and Turakhia 22 the original estimate of $45,372 per QALY was overestimated largely because of the sensitivity of the model to dabigatran drug cost (cost of dabigatran was later found to be $8.00/day, less than the published base-case estimate of $13.00/day) and partially due to the newly identified adverse effects in both the warfarin and dabigatran treatment groups of the RE-LY trial, which caused modest changes to the rates of ischemic stroke, transient ischemic attack, myocardial infarction, and major hemorrhage that were used for this cost-effectiveness study. 22, 23 In summary, annual overall costs for treating AF in the United States are estimated at approximately $6.65 billion, with a national incremental AF cost estimated to range from $6.0 billion to $26.0 billion. [12] [13] [14] On average, annual excess direct costs of treating AF range from $8,705 to $16,311 per patient (vs. non-AF), with total direct costs ranging from $18,454 to $38,270. Annual inpatient costs range from $7,841 to $22,582 per patient. [14] [15] [16] [17] 24 Estimates of ICER for new oral anticoagulants (i.e., dabigatran) ranged from $12,386 to $86,000 per QALY gained with dabigatran versus warfarin. An analysis of 600 adult patients with nonvalvular AF in the United States receiving warfarin at 1 of 3 anticoagulation clinics between 1996 and 1998 was performed. 29 Patients had an average of 18 clinic contacts over a mean follow-up of 10.5 months. Patients were within the recommended INR for 62% of the time, with 25% of days below range and 13% of days above range. The mean per-patient cost of warfarin monitoring for a full year ranged from $216 to $339 (in 2003 U.S. dollars), depending on the site. Adjusting the cost to 2011 U.S. dollars by annual compounding using U.S. Consumer Price Index inflation rates for medical commodities and care for 2003 to 2011 (mean rate, 3.8% 30 ) resulted in a range from $291 to $456 (Figure 1 ). Staff labor costs comprised 40%-50% of the total costs, with almost all of the remaining costs the result of laboratory testing. This study demonstrated that anticoagulation clinics provided a high quality of INR control but required a substantial financial commitment for services that were not frequently reimbursed by payers.
A retrospective cost analysis of anticoagulation therapy in 97 American patients with AF being managed in an outpatient pharmacy anticoagulation service was performed in 2000 to determine the per-patient-per-month (PPPM) cost. 31 The PPPM cost for medications, laboratory, and pharmacist monitoring was found to be $51. Overall, the regular monitoring of INR that is required with warfarin use comes with a financial commitment ranging from $291 to $943 per patient per year in 2011 U.S. dollars.
29,31
The Cost of Managing Bleeding in Patients with AF The most serious consequence of uncontrolled overanticoagulation with warfarin is hemorrhage, particularly intracranial hemorrhage (ICH) or gastrointestinal (GI) bleeding. Although these complications are relatively infrequent, the costs of managing and treating them are high.
A semi-Markov model to assess the costs associated with warfarin was constructed using a hypothetical cohort of 10,000 patients with AF in the United States. 33 The cohort was composed of 70-year-old patients who were identical at baseline apart from their INR values. Twenty scenarios corresponding to adverse events involving ischemic strokes and hemorrhages were modeled. The highest-cost events over 1 year were severe and moderate stroke, with severe lower GI hemorrhage being the third most costly, at $193,804 for warfarin. The least costly of the 20 events were mild ICH or intracerebral hemorrhage ($7,584) and fatal upper GI hemorrhage ($16,781). In this model, the number of fatalities due to hemorrhages exceeded those due to strokes (87.71 vs. 35.02), and the cost of the former was greater than the latter ($929,905 vs. $213,868).
An analysis of medical and pharmacy claims for patients with AF was conducted for bleeding events between 2003 and 2007 to assess the health care costs related to warfarinassociated bleeding in patients with newly diagnosed AF. 34 The analysis included 48,069 subjects with a warfarin claim within 30 days of AF diagnosis. Within 30 days of the warfarin claim during follow-up, 0.4% of patients had an ICH; 1.9% had a major GI bleed; and 3.8% had a minor GI bleed. The mean unadjusted all-cause health care costs in the year after the warfarin index claims were $41,903 (SD $56,654) for patients with at least 1 ICH, $40,586 (SD $65,164) for patients with a major GI bleed, and $24,347 ($56,488) for patients with a minor GI bleed, compared with $24,129 (SD $36,425) for patients with no bleeding events. Adjusting these figures for demographics, insurance types, and comorbidities, the mean adjusted allcause annual costs were $42,574 for patients experiencing an ICH, $36,571 for patients with major GI bleeding, $22,824 for patients with a minor GI bleed, and $22,507 for patients with no bleeding. The higher costs observed in patients with major GI or intracranial bleeding were mainly the result of inpatient service utilization, whereas patients with minor GI bleeding used significantly more outpatient health care resources.
In a study comparing newer oral anticoagulants with warfarin, the rates of clinical events with anticoagulants were estimated as the averages, weighted by patient sample size, from three phase 3 clinical trials, and the event rates for new oral anticoagulants were determined by applying trial hazard ratios or relative risk ratios to such weighted averages. 35 The 3 clinical trials were the following: RE-LY, the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF), and the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. In this comparison, increased costs of major bleedings (excluding hemorrhagic stroke) were associated with dabigatran (+$31/year) and rivaroxaban (+$108/year) usage, while apixaban usage was associated with reductions in costs of major bleedings (-$282/year) relative to warfarin. Notably, the medical cost reduction in this study was driven by clinical outcomes, with drug costs and additional monitoring-related expenses not included. Details of the relationships between clinical outcomes and cost reductions in the trials of the 3 novel oral anticoagulants versus warfarin are compared in Table 1 . 35 The average wholesale prices and monthly costs of oral anticoagulants are listed in Table 2 .
Real-world warfarin use has been reported as inversely related to the CHADS 2 (congestive heart failure, hypertension, age, diabetes, prior stroke or transient ischemic attack) risk score. 36 Specifically, warfarin use declined in patients with increasing risk for stroke, as indexed by higher CHADS 2 scores (P < 0.0001); this change in warfarin use was likely to have been related to the fear of adverse events related to hemorrhage. Thus, it is of interest that Shah and Gage found that regardless of hemorrhage risk, dabigatran was cost-effective in AF populations at high risk of stroke (CHADS 2 ≥ 3). 19 This study was based on a decision analysis (Markov) model and results from the RE-LY trial. Dabigatran was also found to be cost-effective in AF populations with a CHADS 2 score of 2 and high risk of major hemorrhage (> 6%/year). However, the relative advantages of dabigatran over warfarin depended on how well warfarin therapy was managed.
In summary, the major potential complication with any anticoagulant therapy is an increased risk of bleeding, which can be severe and difficult to control. Though ICH and major GI bleeding associated with anticoagulant therapy are rare, they can be costly, with 1-year costs ranging from $7,584 to $193,804. 33, 34 Compared with stroke rate, major bleeding rate appears to have less impact on cost-effectiveness. 42 Most of the costs associated with the complications of AF are due to hospitalization; a systematic literature review estimated that hospitalization represented 50%-70% of the annual direct costs of AF. 43 
Direct Costs of Stroke in Patients with AF Versus Without AF
It is important to appreciate not only that a diagnosis of AF increases the risk of a stroke, with associated increased costs, but also that the costs associated with stroke are higher when a patient has comorbid AF. A diagnosis of AF dramatically increased the total direct health care costs per patient, mainly as a result of complications, in a retrospective, observational cohort study of 3,891 patients in a large managed care organization in the United States between 2000 and 2002. 44 This study found that the total direct health care costs per member per month (PMPM) increased from $412 to $1,235 following the diagnosis of chronic nonvalvular AF. The total direct costs of a cerebrovascular event (transient ischemic attack, ischemic stroke, or major bleed) increased from a range of $392 to $567 PMPM to a range of $1,059 to $2,593 PMPM following the diagnosis of AF. Direct costs for patients with AF who experienced a cerebrovascular event were higher (ranging from $2,235 to $3,135 PMPM) than those without an outcome event (ranging from $865 to $1,324 PMPM). Any warfarin exposure was found to decrease costs by 18% to 29%.
A retrospective analysis of Medicare databases, which assessed the total direct costs of AF in 55,260 patients with AF and the same number of matched controls, also assessed the costs of stroke. In the 1-year post-index period, patients with AF experienced a much higher rate of stroke than subjects without AF (23.1% vs. 13.3%; P < 0.01). A patient with AF who experienced a stroke cost an additional $7,929 relative to an AF patient who did not experience a stroke ($23,143 vs. $15,214; P < 0.01); after adjustment for additional covariates, the incremental costs of stroke on 1-year health care costs were $7,907 ($7,824-8,232).
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Cost of Stroke in Patients with AF Receiving Warfarin
Some studies have considered the contribution of strokes resulting from imperfect warfarin control to the overall cost of stroke in patients with AF. A disease model using 2003 Medicare cost data was applied to estimate the economic burden of stroke in 2.3 million U.S. patients with AF. 45 Using the model, 58,392 strokes were estimated to occur per year in the 1.265 million patients not receiving anticoagulants and 38,468 strokes in the 1.035 million patients receiving anticoagulants. These strokes were estimated to cost nearly $8 billion, with $2.6 billion in the year of the event itself and $5.4 billion in subsequent years. This equated to $3,435 per AF patient or $286 PPPM. The perpatient cost of management in an anticoagulation clinic was $1,485 compared with $3,710 for routine medical care and $3,778 for patients not receiving any oral anticoagulation. The
Estimates of medical cost (driven by clinical outcomes) of new oral anticoagulants suggest a slightly increased cost of major bleedings-excluding hemorrhagic stroke-with dabigatran and rivaroxaban usage ($31/year and $108/year, respectively), whereas apixaban usage was associated with reductions in costs of major bleedings (-$282/year) relative to warfarin. 35 A confounding issue with these new oral anticoagulants is the possibility that major bleeding events may be more costly than those with warfarin because of the lack of an available specific antidote. 37 Because of the short half-life of these new anticoagulants (approximately 5-14 hours), 38 -40 discontinuation of therapy may be sufficient for hemorrhagic events except in patients with bleeding that is in critical organs (e.g., intracranial hemorrhage) or is immediately life-threatening. 21, 41 Thus, the lack of a specific antidote may not be a major drawback in the majority of bleeding situations, as there may be relatively few circumstances in which a reversal agent will be required. 37 However, the lack of antidote and its impact on cost remain to be seen.
The Cost of Stroke in Patients with AF
Stroke is the most feared complication of AF and is the reason warfarin is prescribed. Stroke and heart failure (the other major complication of AF) are responsible for the majority of excess costs associated with the condition. For example, a cost analysis from 2007 estimated that the direct cost of complications of AF (stroke and heart failure) represented 54% of the Finally, a study conducted on 67,077 Veterans Health Administration patients anticoagulated for AF simulated the number of adverse events and their associated costs and utilities, both before and after various degrees of improvement in percent time in therapeutic range (TTR). The authors reported that 5% improvement in TTR prevented 1,114 adverse events, resulting in a gain of 863 QALY and savings of $15.9 million compared with the baseline. One-time costs of ischemic stroke with moderate to severe sequelae and minor sequelae were $15,497 and $9,562, respectively, while monthly (long term) cost of ischemic stroke with moderate to severe sequelae and minor sequelae were $5,605 and $2,528, respectively, 47 with annual inflation rates 2008 to 2011, 3.2%.
In summary, stroke is the most serious and debilitating of all the complications of AF. Severe stroke and moderate stroke were predicted to be the most costly events in patients with AF, at $1,758,540 and $380,355 total costs for 1 year, respectively. 33 Analyses of managed care databases indicate that AF patients who experienced a stroke had increased annual direct costs (range $23,143 to $37,620) relative to AF patients who did not experience a stroke ($10,380 to $15,888). 15, 16, 44 Of AF patients who experienced a stroke or other cerebrovascular event, those who received warfarin had lower direct costs ($26,640-$26,820) than AF patients who did not receive warfarin ($32,664-$37,620). 44 Cost-effectiveness models estimate the cost of stroke in AF patients to range from $68,039 (for perfect warfarin use) to $87,248 (for approximated routine practice where a proportion of warfarin-eligible patients are prescribed aspirin or neither warfarin nor aspirin). 46 The burden of AF-related stroke is estimated at nearly $8 billion, with $2.6 billion in the year of the event itself and $5.4 billion in subsequent years. 45 A systematic literature review of the cost burden of ischemic stroke found that much of the literature focused on short-term, in-hospital expenditures, which were estimated to be approximately $8,000 to $23,000 in 2008 U.S. dollars, depending on the length of stay. 48 However, there appeared to be a scarcity in the literature regarding the long-term costs of stroke care.
■■ Discussion
This literature review has demonstrated that the direct costs associated with AF are high and that these can be broken down into the costs of monitoring warfarin and the direct health care costs of managing the consequences of anticoagulant therapy-stroke and bleeding-in addition to the costs of the drug. Being able to have these associated costs at hand can assist in making more informed decisions about the cost-effectiveness of one new agent versus another.
The costs of monitoring warfarin therapy ranged from $291 to $943 per patient per year in 2011 U.S. dollars. Menzin et al.
high cost of anticoagulation in routine medical care included the costs necessary to treat complications of anticoagulation therapy (e.g., GI bleeding). Two scenarios were posited. In the first, if half of the patients who were not receiving warfarin were to receive well-controlled warfarin, approximately 19,000 strokes per year would be prevented, and $1.1 billion would be saved in direct costs. In the second scenario, if half of the patients receiving warfarin in routine medical care were to have their warfarin optimized, 9,000 strokes and 29,000 bleeds would be prevented, at a savings of $1.3 billion.
In the semi-Markov model of 10,000 patients with AF receiving stroke prophylaxis with warfarin constructed by Leigh and White (2007) , 33 severe stroke and moderate stroke were predicted to be the most costly events in patients with AF, at $1,758,540 and $380,355 for 1 year, respectively. Overall, the model predicted 490 moderate and severe strokes over the year, at a cost of $11,154,508. Furthermore, although the number of severe ischemic strokes was similar to the number of severe hemorrhages, they cost considerably more: $9,283,306 for 256 strokes, compared with $3,645,711 for 276 severe bleeds. 33 The increased cost of severe strokes was related to the need for rehabilitation and skilled nursing home stays, which were not needed with severe bleeding.
A cost-effectiveness model was used to predict the rate of stroke in 4 hypothetical scenarios: (1) all patients start on warfarin with perfect control; (2) all patients start on warfarin with trial-like control, with INR falling outside of the recommended range; (3) all patients start on warfarin with real-world INR control; and (4) real-world prescription and control of warfarin, aspirin, or neither (i.e., where a proportion of warfarin-eligible patients are prescribed either aspirin [12%] or neither warfarin nor aspirin [23%]). 46 Reported discontinuation rates were used. The total number of primary and secondary ischemic strokes in a cohort of 1,000 patients ranged from 626 to 1,171 in scenarios 1 to 4, respectively. The costs per patient ranged from $68,039 to $87,248 in scenarios 1 to 4, respectively; when long-term disability costs were excluded, these cost estimates decreased to $17,000 to $21,000. Perfect adherence to warfarin was shown to reduce the rate of strokes significantly. This study showed that clinical and cost outcomes were strongly dependent on the quality of anticoagulation and rates of warfarin discontinuation; therefore, both should be improved. The authors noted that real-world INR control and warfarin discontinuation rates should be considered when assessing cost-effectiveness.
In the analyses conducted by Boccuzzi et al. (2009) , the total direct costs associated with nonvalvular AF and the occurrence of cerebrovascular events (transient ischemic attack, ischemic stroke, or major bleed) were found to be less in AF patients who received warfarin (ranging from $2,220 to $2,235 PPPM) than those who did not (ranging from $2,722 to $3,135 PPPM). 44 Translated to 1-year costs, AF patients who received warfarin (2005) indicate that if 50% of the 2.2 million persons in the United States with AF received warfarin, the costs of monitoring warfarin therapy would exceed $300 million annually. 29 Another cost of regular laboratory monitoring to consider is the cost to patients, such as the cost of transportation and time lost from work. Hwang et al. (2011) determined the average cost of round-trip transportation to be $10.78 in 2010 U.S. dollars weighted for all transportation modes based on a 60-patient survey at an urban anticoagulation clinic. 49 The annual cost of round-trip transportation ranged from $130 (monthly appointments) to $560 (weekly appointments). Since most participants were unemployed or retired, only 7 of the 60 participants took time off from work for clinic visits. However, for these individuals, the mean missed work time (including travel time) was 1.75 hours per visit. Considering average hourly earnings of $23.75 (in 2012 U.S. dollars), calculated by the U.S. Bureau of Labor Statistics, 50 the indirect cost of time lost from work was $41.56 per visit, ranging from $498.75 (monthly appointments) to $2,161.25 (weekly appointments) per year.
Comorbidities for AF patients may also disrupt oral anticoagulant therapy and increase the amount of management required to stabilize anticoagulant concentrations in the plasma. Kleinow et al. (2011) showed that patients with chronic kidney disease (CKD) required a 24% (mean: 35.9 vs. 47.0 mg per week, P = 0.003) lower dose than the patients without CKD and spent less time in therapeutic range, which increased clinic management versus the comparison group. 51 This conclusion was supported by a significantly higher number of clinic visits for dose change (22% vs. 12%, P < 0.001) and a decreased time between scheduled visits (mean length 16 days vs. 19.7 days, P = 0.001). 51 The major potential complication with any anticoagulant therapy is an increased risk of bleeding, which can be severe and difficult to control. Though ICH and major GI bleeding associated with anticoagulant therapy are rare, they can be costly, with 1-year costs ranging from $7,584 to $193,804. 33, 34 Compared with stroke rate, major bleeding rate appears to have less effect on cost-effectiveness. A confounding issue with the new oral anticoagulants is the lack of an available specific antidote. The impact of this on management of AF and overall costs remains to be seen.
Annual direct costs of stroke in AF patients range from $23,143 to $37,620 with an incremental cost of $7,824 to $8,232 (vs. AF patients without stroke). The lower rates of stroke and systemic embolism associated with new oral anticoagulants may result in lower costs and reduce the overall burden of AF-related stroke. Additionally, compared with warfarin, the efficacy of new oral anticoagulants, such as rivaroxaban, was as favorable in centers with the best INR control as with poorer INR control. 10 Warfarin underuse is well documented in real-world populations and compliance with antithrombotic therapy, particularly with warfarin, is lower in practice than in clinical trials; an estimated 50% to 60% of patients appropriately use warfarin. [52] [53] [54] [55] Economic models suggest that if just half of all patients with AF currently receiving suboptimal or no anticoagulation could be optimized-whether via optimal warfarin use or use of one of the new oral anticoagulants-the United States could save approximately $2.5 billion in total direct costs every year. 45 Increased adherence to oral anticoagulants is important in preventing stroke and would contribute to better outcomes in real-world populations and reduced costs. 45, 52 Brown et al. (2012) built a model to consider adherence to oral anticoagulants that summarized results from 4 patient focus groups, supported and augmented by literature review. 56 Several of the themes in the model, such as avoidance of negative health consequences or developing a routine for therapy management, would be enhanced by the newer anticoagulants as opposed to warfarin. 56 Thus, the use of newer agents, requiring less monitoring, may improve patient compliance with anticoagulant therapy.
■■ Conclusions
When considering the cost implications of anticoagulants for stroke prophylaxis in patients with AF, the costs of monitoring warfarin and the costs of the consequences of suboptimal anticoagulation must be considered. Adequate, thorough, and comprehensive sources to determine these costs are currently lacking from the literature. Cost-effectiveness studies comparing newer anticoagulants to warfarin are warranted. Thus far, economic analyses comparing newer anticoagulants with warfarin have been largely based on clinical trial data and decision-analysis models. The direct application of these results to the real-world setting will require further assessment. Many factors, including local health care costs, drug adherence, population risk, and health behaviors may vary and require further assessment. The cost of anticoagulants must be offset against the multiple ancillary costs discussed in this review when comparing with the new oral anticoagulants.
